Healthcare | August 03, 2021
Meddo acquires Doxper in a cash and stock deal
This deal makes Meddo, one of the largest health-tech players in India
This deal makes Meddo, one of the largest health-tech players in India
The govt has rolled out three schemes for promoting the manufacture of API
Drug formulations and biologics make impressive gains
The Phase III clinical trial for NONS is expected to be completed by Q4 2021.
India business is growing as per projections; whereas US business will bounce back soon.
Ayush Ministry will conduct the study along with the UK’s London School of Hygiene and Tropical Medicine
Proceeds from the IPO will be used for the expansion of the Dehradun facility.
Price band in the range of Rs 933 to Rs 954
The company posted net profit of Rs.89.20 crores for the period ended June 30, 2020.
The new greenfield manufacturing facility will be operated alongside the Guwahati facility as a parallel unit thereby helping mitigate the risks of a single-location operation
Subscribe To Our Newsletter & Stay Updated
